X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Divis Laboratories with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs TEVA PHARMA (Israel) - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DIVIS LABORATORIES   TEVA PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
TEVA PHARMA
Dec-13
DIVIS LABORATORIES/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2222,664-   
Low Rs7842,314-   
Sales per share (Unadj.) Rs153.11,528.8-  
Earnings per share (Unadj.) Rs39.995.5-  
Cash flow per share (Unadj.) Rs44.6219.1-  
Dividends per share (Unadj.) Rs10.0083.60-  
Dividend yield (eoy) %1.03.4 29.7%  
Book value per share (Unadj.) Rs201.81,698.2-  
Shares outstanding (eoy) m265.47848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.61.6 402.4%   
Avg P/E ratio x25.126.1 96.3%  
P/CF ratio (eoy) x22.511.4 198.0%  
Price / Book Value ratio x5.01.5 339.1%  
Dividend payout %25.087.5 28.6%   
Avg Mkt Cap Rs m266,2662,110,655 12.6%   
No. of employees `0009.744.9 21.7%   
Total wages/salary Rs m4,6870-   
Avg. sales/employee Rs Th4,175.028,845.0 14.5%   
Avg. wages/employee Rs Th481.50-   
Avg. net profit/employee Rs Th1,089.31,801.9 60.5%   
INCOME DATA
Net Sales Rs m40,6431,296,439 3.1%  
Other income Rs m7490-   
Total revenues Rs m41,3921,296,439 3.2%   
Gross profit Rs m14,460355,031 4.1%  
Depreciation Rs m1,233104,792 1.2%   
Interest Rs m2325,464 0.1%   
Profit before tax Rs m13,953224,774 6.2%   
Minority Interest Rs m01,021 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-147,552 0.0%   
Tax Rs m3,349-2,744 -122.0%   
Profit after tax Rs m10,60480,988 13.1%  
Gross profit margin %35.627.4 129.9%  
Effective tax rate %24.0-1.2 -1,966.0%   
Net profit margin %26.16.2 417.7%  
BALANCE SHEET DATA
Current assets Rs m40,105875,610 4.6%   
Current liabilities Rs m6,595763,606 0.9%   
Net working cap to sales %82.58.6 954.4%  
Current ratio x6.11.1 530.4%  
Inventory Days Days11991 130.6%  
Debtors Days Days8196 84.1%  
Net fixed assets Rs m19,995423,446 4.7%   
Share capital Rs m5313,191 16.6%   
"Free" reserves Rs m53,0430-   
Net worth Rs m53,5741,440,098 3.7%   
Long term debt Rs m0662,898 0.0%   
Total assets Rs m61,5852,962,780 2.1%  
Interest coverage x618.49.8 6,292.9%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.70.4 150.8%   
Return on assets %17.33.6 480.3%  
Return on equity %19.85.6 352.0%  
Return on capital %26.14.9 529.0%  
Exports to sales %00-   
Imports to sales %25.20-   
Net fx Rs m24,9850-   
CASH FLOW
From Operations Rs m11,493206,585 5.6%  
From Investments Rs m-11,372-73,202 15.5%  
From Financial Activity Rs m-93-247,813 0.0%  
Net Cashflow Rs m28-114,429 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 63.82 Rs / USD

Compare DIVIS LABORATORIES With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare DIVIS LABORATORIES With: WOCKHARDT LTD.  DR. REDDYS LAB  PIRAMAL ENTERPRISES  SUVEN LIFE  ALKEM LABORATORIES  



Today's Market

Sensex Surges 300 Points; Tata Steel Up 3.5%(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading near all-time high levels. Sectoral indices are trading on a positive note.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 23, 2018 03:34 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS